# A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors

> **NCT05908773** · EARLY_PHASE1 · COMPLETED · sponsor: **TransCode Therapeutics** · enrollment: 1 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TTX-MC138-NODAGA-Cu64

## Key facts

- **NCT ID:** NCT05908773
- **Lead sponsor:** TransCode Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-04
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-09-18
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05908773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05908773, "A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05908773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*